NLK and anemia (phenotype): It has been reported that metformin induces the expression of miR-26a and recognizes the binding site within the 3′-UTR of Nemo-like kinase (NLK) to promote the degradation of NLK transcripts, thereby promoting erythroid differentiation and improving anemia in DBA patients.94 Similarly, ginsenoside Rb1 upregulates the expression of miR-208, which binds the 3′-UTR of NLK mRNA and targets it for degradation, thereby improving abnormal erythropoiesis in DBA patients.95